arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Schrodinger, Inc.

SDGR
$29.22 ▼ -1.50 (-4.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Schrodinger, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B
Dividend Yield —
Revenue Growth 7.5% ↗
Op. Margin -70.6% ↗
ROIC -10.3% ↗
FCF / Share $-0.46 ↘
Trailing P/E 365.3x
Price / Book 6.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$58.89M
↑ +7.5% —
Net Income Profit after all expenses
$5.97M
↑ +110.0% —
Operating Margin Operating profit as % of sales
-70.6%
↑ +15.3% 4th
FCF / Share Free cash flow per share
$-0.46
↓ -96.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
18
Returns ↓
24
Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 30 quarters